Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;4(3):166-73.
doi: 10.1556/EUJMI-D-14-00014. Epub 2014 Sep 11.

Assessment of the genotype MTBDRplus assay for rifampin and isoniazid resistance detection on sputum samples in Cote d'Ivoire

K N'guessan, J S Assi, T Ouassa, J M Ahui-Brou, A Tehe, M Keita Sow, A Guei, J Kouakou, M Dosso

Assessment of the genotype MTBDRplus assay for rifampin and isoniazid resistance detection on sputum samples in Cote d'Ivoire

K N'guessan et al. Eur J Microbiol Immunol (Bp). 2014 Sep.

Erratum in

  • Erratum.
    N'guessan K, Assi JS, Ouassa T, Ahui-Brou JM, Tehe A, Keita Sow M, Guei A, Kouakou J, Dosso M. N'guessan K, et al. Eur J Microbiol Immunol (Bp). 2014 Dec;4(4):223-4. doi: 10.1556/EuJMI.4.2014.4.0. Epub 2014 Dec 16. Eur J Microbiol Immunol (Bp). 2014. PMID: 25544429 Free PMC article.

Abstract

We conducted an evaluation study on the GenoType MTBDRplus assay's ability to detect mutations conferring resistance to rifampin and isoniazid directly from sputum taken from 120 smear positive pulmonary patients from tuberculosis (TB) centers in Cote d'Ivoire. The sputum was decontaminated by N-acetyl-l-cysteine (NALC) and comparatively analyzed with the MTBDRplus assay version 2.0 and the mycobacterial growth indicator tube (MGIT) 960 automated drug susceptibility testing (MGIT-DST). The Gene-Xpert Mycobacterium tuberculosis (MTB)/rifampicin (RIF) assay was performed for 21 sputa with absence of hybridization for at least one rpoB wild-type probes. Four and seven, respectively, discordant and concordant results were also analyzed. The mutations in the rpoB gene were 21 (17.5%), 20 (16.7%), 7 (5.8%), and 10 (8.3%), respectively, for D516V, H526Y, H526D, and S531L. S315T mutation in katG gene associated or not with mutation in promoter of inhA was detected in 76 (63.3%) of the sputum. Compared to MGIT-DST, the sensitivity and specificity of the MTBDRplus for rifampin resistance detection were 100% (75-100%) and 73.2% (61.3-84%), respectively. For isoniazid resistance detection, the sensitivity and specificity were, respectively, 95% (90-‌99) and 95.1% (88.5-100%). Interpretation of 16 sputa without hybridization of rpoB wild-type probe 8 compared to those obtained with MGIT-DST and GeneXpert MTB/RIF was discordant and concordant, respectively, for 11 and 5.

Keywords: assessment; drug-resistance; isoniazid; molecular assay; rifampin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest. None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this article.

References

    1. The World Health Organization (WHO) – International Union Against Tuberculosis and Lung Disease (IUATLD) Global project on antituberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world: fourth global report. WHO/HTM/TB/2008.394. World Health Organization; 2008.
    1. García de Viedma D. Rapid detection of resistance in Mycobacterium tuberculosis: a review discussing molecular approaches. Clin Microbiol Infect. 2003 May;9(5):349–359. doi: 10.1046/j.1469-0691.2003.00695.x. - DOI - PubMed
    1. World Health Organization. Global Tuberculosis: WHO report 2013. WHO/HTM/TB/2013.11. World Health Organization; 2013.
    1. N'guessan K, Dosso M, Nahoua I, Koffi MS, Kouakou J. Primary resistance to antituberculosis drugs: trends in Cote d'Ivoire from 1995 to 2006. Med Mal Infect. 2008 Apr;38(4):231–232. doi: 10.1016/j.medmal.2007.11.004. - DOI - PubMed
    1. N’Guessan K, Ouassa T, Assi JS, Tehe A, Assande JM, et al. Molecular detection of resistance to rifampin and isoniazid among patients eligible for retreatment regimen in Côte d’Ivoire in 2012. Adv Infect Dis. 2013;3:65–70.